LONDON - Members of the UK biotech industry met last week to discuss how they are coming to terms with the practical consequences of the disastrous TGN1412 clinical trial, and in particular the extra scrutiny to which biological products with novel modes of action are now subjected when moving into first-in-human trials. (BioWorld International) Read More
